Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 8
- 13F valueReported value at the end of Q2 2026
- $187.1K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding JSPRW, Q2 2026
No superinvestor reported holding JSPRW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Jasper Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 22, 2026 (view filing)7:10 PM ET | Jul 20 | 2 days | Ros Matthew EChief Operating Officer | PPurchaseVoting Common Stock | +53.7K | – | – | –881 after | Derivative |
| Jul 20, 2026 (view filing)8:38 PM ET | Jul 20 | Same day | Crutcher Patrick JDirector | PPurchaseVoting Common Stock | +888 | – | – | –888 after | Derivative |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Wiggans Thomas GDirector | PPurchaseVoting Common Stock | +41.0K | $2.43 | +$99.6K | New position41.0K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Wiggans Thomas GDirector | PPurchaseVoting Common Stock | +41.0K | – | – | –41.0K after | DerivativeDuplicate filing |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Lucas SvetlanaDirector | PPurchaseVoting Common Stock | +20.0K | $2.43 | +$48.6K | New position20.0K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Lucas SvetlanaDirector | PPurchaseVoting Common Stock | +20.0K | – | – | –20.0K after | Derivative |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Martell RonPresident and CEO | PPurchaseVoting Common Stock | +41.0K | $2.43 | +$99.6K | +123.8%74.1K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Martell RonPresident and CEO | PPurchaseVoting Common Stock | +41.0K | – | – | –41.0K after | Derivative |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Shizuru Judith AnneDirector | PPurchaseVoting Common Stock | +41.0K | $2.43 | +$99.6K | +35.4%156.9K after | |
| Sep 24, 2025 (view filing) | Sep 22 | 2 days | Shizuru Judith AnneDirector | PPurchaseVoting Common Stock | +41.0K | – | – | –41.0K after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Jasper Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Boothbay Fund Management, LLC | 357,447 | $150.5K | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 2,174,682 | $30.4K | 0.00% | −1000.0% | Reduced |
| Tenor Capital Management Co., L.P. | 250,000 | $3.38K | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 200,000 | $2.70K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | – | $40 | 0.00% | – | – |
| Wolverine Asset Management LLC | 1,639 | $22 | 0.00% | +600+57.7% | Added |
| IFP Advisors, Inc | 50 | $1 | 0.00% | 00.0% | Unchanged |
| SkyView Investment Advisors, LLC | 302 | $0 | 0.00% | +302 | New |